Trusted Resources: Education
Scientific literature and patient education texts
Mucopolysaccharidosis III: Molecular Basis and Treatment
source: Pediatric endocrinology, diabetes, and metabolism
year: 2021
authors: Spahiu L,Behluli E,Peterlin B,Nefic H,Hadziselimovic R,Liehr T,Temaj G
summary/abstract:Mucopolysaccharidoses (MPSs) are known as rare genetic diseases which are caused by mutation in the enzyme heparin sulfate, which normally leads to degradation and accumulation of glycosaminoglycans in the cells. There are 11 types of MPSs, whereby neuropathy may occur in seven of them (MPS I, II, IIIA, IIIB, IIIC, IIID and VII). Accumulation of degraded heparin sulfate in lysosomes causes cellular dysfunction and malfunction of several organs. However, the exact molecular mechanism how protein degradation and storage leads to cellular dysfunction is not understood, yet. Nonetheless, several genetic and biochemical methods for diagnosis of MPSs are available nowadays. Here we provide an overview on known molecular basis of MPS in general, including enzyme defects and symptoms of MPS; however, the main focus is on MPS type III together with potential and perspective therapy-options.
organization: Pediatric Clinic, University Clinical Center of Kosovo, Prishtina, Kosovo.DOI: 10.5114/pedm.2021.109270
read more
Related Content
-
Sanfilippo Ideal for FDA’s Accelerated Approval Pathway, Foundation SaysThe Cure Sanfilippo Foundation is encour...
-
New Type A ERT Candidate on Track for Clinical TrialJapanese company, JCR Pharmaceuticals, h...
-
Glenn O’NeillSince its creation, the Foundation has g...
-
Sanfilippo Children’s Foundation – TwitterSanfilippo Childrens foundation is dedic...
-
Europe Grants Orphan Drug Status to JR-441, ERT for Sanfilippo AThe European Commission has granted an o...
-
Long-Term Safety and Clinical Outcomes of Intrathecal Heparan-N-Sulfatase in Patients With Sanfilippo Syndrome Type ...Currently, there is no effective therapy...
-
Advocacy Groups Unveil ‘Roadmap’ for Sanfilippo Research, CareA coalition of patient advocacy organiza...